Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection.

Shuqun C, Mengchao W, Han C, Feng S, Jiahe Y, Wenming C, Zhengfeng Y, Yuxiang Z, Peijun W

Hepato-gastroenterology1 Mar 2006Cited by 29 (Europe PMC)

PMID16608033PepBankPUB-16608033

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

01HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In patients with hepatocellular carcinoma and chronic hepatitis B, postoperative lamivudine plus thymosin alpha1 gave a higher one-year HBV-DNA suppression rate than hepatectomy only (100% vs. 6%).
In plain wordsIn patients with liver cancer and hepatitis B, lamivudine plus thymosin alpha1 after surgery suppressed hepatitis B virus DNA more often than surgery alone.
Peptide
Thymosin alpha-1
Outcome
IncreaseOne-year HBV-DNA suppression rate
Study
n = 33
Comparator
Hepatectomy only
Outcome group
Antiviral activity · Infection
Measurements
HBV-DNA suppression rate, one year
100%
treatment group
HBV-DNA suppression rate, one year
6%
control group
Source sentences
Summary
the one-year HBV-DNA suppression rate was 100% vs. 6% (p=0.0016)
1 context sentence(design, population, supporting numbers)
Summary · context
2002, 33 patients with HCC coexisting chronic hepatitis B infection with active virus replication were prospectively divided into two groups: control group (n= 17) received hepatectomy only, treatment group (n= 16) received hepatectomy and lamivudine plus thymosin alpha1 therapy postoperatively.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1660803301
02HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In patients with hepatocellular carcinoma and chronic hepatitis B, postoperative lamivudine plus thymosin alpha1 gave a higher HBeAg seroconversion rate than hepatectomy only (62.5% vs. 5.9%).
In plain wordsIn patients with liver cancer and hepatitis B, lamivudine plus thymosin alpha1 after surgery led to more HBeAg seroconversion than surgery alone.
Peptide
Thymosin alpha-1
Outcome
IncreaseHBeAg seroconversion rate
Study
n = 33
Comparator
Hepatectomy only
Outcome group
Antiviral activity · Infection
Measurements
HBeAg seroconversion rate
62.5%
treatment group
HBeAg seroconversion rate
5.9%
control group
Source sentences
Summary
HBeAg seroconverted rate was 62.5% vs. 5.9% (p=0.0157)
1 context sentence(design, population, supporting numbers)
Summary · context
2002, 33 patients with HCC coexisting chronic hepatitis B infection with active virus replication were prospectively divided into two groups: control group (n= 17) received hepatectomy only, treatment group (n= 16) received hepatectomy and lamivudine plus thymosin alpha1 therapy postoperatively.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1660803302
03HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In patients with hepatocellular carcinoma and chronic hepatitis B, postoperative lamivudine plus thymosin alpha1 lengthened the median time to recurrence versus hepatectomy only (7.0 vs. 5.0 months).
In plain wordsIn patients with liver cancer and hepatitis B, lamivudine plus thymosin alpha1 after surgery delayed tumour return compared with surgery alone.
Peptide
Thymosin alpha-1
Outcome
IncreaseMedian time to tumour recurrence
Study
n = 33
Comparator
Hepatectomy only
Outcome group
Tumor growth · Cancer
Measurements
Median recurrence time
7 months
treatment group
Median recurrence time
5 months
control group
Source sentences
Summary
The median recurrent time was 7.0 vs. 5.0 months (p=0.0052)
1 context sentence(design, population, supporting numbers)
Summary · context
2002, 33 patients with HCC coexisting chronic hepatitis B infection with active virus replication were prospectively divided into two groups: control group (n= 17) received hepatectomy only, treatment group (n= 16) received hepatectomy and lamivudine plus thymosin alpha1 therapy postoperatively.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1660803303
04HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In patients with hepatocellular carcinoma and chronic hepatitis B, median survival did not differ significantly between postoperative lamivudine plus thymosin alpha1 and hepatectomy only (10.0 vs. 7.0 months, p=0.10053).
In plain wordsIn patients with liver cancer and hepatitis B, survival with lamivudine plus thymosin alpha1 after surgery was not significantly different from surgery alone.
Peptide
Thymosin alpha-1
Outcome
No significant changeMedian survival
Study
n = 33
Comparator
Hepatectomy only
Outcome group
Mortality · Cancer
Measurements
Median survival
10 months
treatment group
Median survival
7 months
control group
Source sentences
Summary
The median survival period was 10.0 vs. 7.0 months (p=0.10053)
1 context sentence(design, population, supporting numbers)
Summary · context
2002, 33 patients with HCC coexisting chronic hepatitis B infection with active virus replication were prospectively divided into two groups: control group (n= 17) received hepatectomy only, treatment group (n= 16) received hepatectomy and lamivudine plus thymosin alpha1 therapy postoperatively.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1660803304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.